High Risk of Bias in Early COVID-19 Studies: Meta-Analysis
High Risk of Bias in Early COVID-19 Studies: Meta-Analysis
Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.
High Risk of Bias in Early COVID-19 Studies: Meta-Analysis
High Risk of Bias in Early COVID-19 Studies: Meta-Analysis

Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.

Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.

clinical research
Liver Dysfunction: Causes and Mechanisms<br>
Liver Dysfunction: Causes and Mechanisms
The Scientist Creative Services Team | Dec 21, 2020
Learn about the underlying causes and mechanisms behind liver pathophysiology.
RNA Interference Comes of Age
RNA Interference Comes of Age
Diana Kwon | Dec 9, 2020
The third FDA approval of an RNAi-based therapeutic marks the growing success of a technique that took two decades to get off the ground.
Distinct Microbiome and Metabolites Linked with Depression
Distinct Microbiome and Metabolites Linked with Depression
Rachael Moeller Gorman | Dec 9, 2020
The gastrointestinal tracts of people with major depressive disorder harbor a signature composition of viruses, bacteria, and their metabolic products, according to the most comprehensive genomic and metabolomic analysis in depression to date.
Opinion: Emergency Use Authorizations Are a Threat to Science<strong>&nbsp;</strong>
Opinion: Emergency Use Authorizations Are a Threat to Science 
Kevin J. Tracey, Christina Brennan | Dec 1, 2020
As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.
The Promise of mRNA Vaccines
The Promise of mRNA Vaccines
Diana Kwon | Nov 25, 2020
Long before Moderna’s and Pfizer’s COVID-19 shots, scientists had been considering the use of genetically encoded vaccines in the fight against infectious diseases, cancer, and more.
CRISPR Technologies for the New Era of Cell and Gene Therapy
CRISPR Technologies for the New Era of Cell and Gene Therapy
The Scientist Creative Services Team | Nov 25, 2020
Experts will discuss how they use new CRISPR technologies to advance their cell and gene therapy research.
Moderna&rsquo;s COVID-19 Vaccine 94 Percent Effective: Initial Data
Moderna’s COVID-19 Vaccine 94 Percent Effective: Initial Data
Max Kozlov | Nov 16, 2020
The results mark the second experimental COVID-19 vaccine to show high efficacy, but the study is not complete and the data have not been peer reviewed.
Updated
Pfizer&rsquo;s COVID-19 Vaccine 90 Percent Effective: Initial Data
Pfizer’s COVID-19 Vaccine 90 Percent Effective: Initial Data
Max Kozlov | Nov 9, 2020
Vaccine experts say the results surpass their expectations, but the study is not complete, and the data have not been peer reviewed.
Scientists Probe Blockers for the Coronavirus Spike Protein
Scientists Probe Blockers for the Coronavirus Spike Protein
Anthony King | Nov 5, 2020
SARS-CoV-2, the virus that causes COVID-19, taps into human proteases such as furin to enter cells. Temporarily inhibiting those enzymes might stymie infection.